Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

A BRAF mutation is a form of cancer in which the BRAF gene begins to cause certain cells to continue dividing without ever receiving a signal to stop. The V600E variant is one of the more common ...

The efficacy signal was strong with 93% of patients seeing ... It is applicable to pLGG patients, but only in BRAF V600 mutations, which comprise 20% of the addressable market, leaving 80% of ...

Q4 2024 Earnings Call Transcript February 27, 2025 Cardiff Oncology, Inc. beats earnings expectations. Reported EPS is $-0.22 ...

Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectivelyEnded 2024 with ...

BRAF V600E-mutated colorectal cancer represents ... At the same time, the interim overall survival signal also provided the FDA extra comfort.

Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...

Overall, we were pleased with the efficacy signal observed in the trial ... its drug encorafenib in first-line mCRC patients, with a BRAF mutation. And to be clear, this is a totally separate ...

BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in a Phase III trial, further supporting a full ...

A BRAF mutation is a form of cancer in which the BRAF gene begins to cause certain cells to continue dividing without ever receiving a signal to stop. The V600E variant is one of the more common forms ...